Evidence map›Paper›PMID 29243850›Full record

ArticleAlimentary pharmacology & therapeutics2018

Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males.

M Song, M C Camargo, S J Weinstein, G Murphy, N D Freedman, J Koshiol, R Z Stolzenberg-Solomon, C C Abnet, S Männistö, D Albanes and 1 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06581796 (Examination of the Maternal Serum Pepsinogen-1 in Patients Diagnosed With Severe Hyperemesis Gravidarum), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06581796 completednot on this mapstarted 2024, after this paper: background citation

Examination of the Maternal Serum Pepsinogen-1 in Patients Diagnosed With Severe Hyperemesis Gravidarum: A Prospective Case-control Study

Typeobservational_patient_registrySponsorAnkara Etlik City HospitalRan2024 to 2024Enrolled40ConditionsHyperemesis Gravidarum, Pregnant With ComplicationArmspepsinogen-1
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Human gastric cancer risk screening: From rat pepsinogen studies to the ABC method.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2021
    Article
  10. Association ofCanadian journal of gastroenterology & hepatology · 2021
    Review
  11. Review
  12. Article
  13. Helicobacter pylori Infection: New Facts in Clinical Management.Current treatment options in gastroenterology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

M SongDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-9412-2871
M C CamargoDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
S J WeinsteinDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
G MurphyDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-0118-5337
N D FreedmanDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
J KoshiolDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
R Z Stolzenberg-SolomonDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
C C AbnetDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
S MännistöDepartment of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.
D AlbanesDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
C S RabkinDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
National Institutes of Health · USFinnish Institute for Health and Welfare · FI

Funding

Infections, immunity, and inflammation in cancerZIACP010150 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2009 to 2025
$24.0M
Molecular mechanisms of infection-related cancerZIACP010212 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2010 to 2025
$4.6M
Infections, immunity, and inflammation in cancerZ01CP010150 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2000 to 2008
$3.0M
Intramural NIH HHS Z01 CP010150NCI NIH HHS HHSN261201500005C
6 · The paper itself

Abstract

backgroundSerum pepsinogen 1 (SPG1) and anti-Helicobacter pylori serology have been used for gastric risk stratification in Asia.

aimTo assess utility of these markers in a Western population.

methodsSPG1 measurements were available for 21 895 Finnish male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. We used Cox proportional hazards models adjusted for potential confounders to estimate gastric cancer hazard ratios (HR) and 95% confidence intervals (95% CI) for low SPG1 (<25 μg/L). In a subset (n = 3555) with anti-H. pylori serology, these markers jointly defined the following: Group A (H. pylori[-], SPG1[normal]; reference group), Group B (H. pylori[+], SPG1[normal]), Group C (H. pylori[+], SPG1[low]) and Group D (H. pylori[-], SPG1[low]). Odds ratios (ORs) and 95% CI were calculated using multivariate logistic regression.

resultsThere were 329 gastric cancers diagnosed an average of 13.9 years after baseline. Pre-diagnostic low SPG1 was significantly associated with increased gastric cancer risk (HR 2.68, 95% CI 1.99-3.61). Among subjects with both SPG1 and H. pylori serology, groups B, C and D had increased gastric cancer ORs (95% CI) of 1.79 (1.21-2.64), 3.85 (2.36-6.28) and 6.35 (2.20-18.34), respectively. CagA seropositives had significantly higher ORs than CagA seronegatives within group B (P

conclusionsLow SPG1 was associated with increased gastric cancer risk in our large Finnish cohort. A single measurement of SPG1 along with H. pylori whole cell and CagA serology provides potentially useful prediction of gastric cancer risk.

Indexed as

AgedAntibodies, BacterialBiomarkersCohort StudiesFinlandHelicobacter InfectionsHelicobacter pyloriHumansImmunoglobulin GMaleMiddle AgedPepsinogen APrognosisRandomized Controlled Trials as TopicRegistriesRisk FactorsAntibodies, BacterialBiomarkersImmunoglobulin GPepsinogen A

Identifiers

PMID29243850
PMCPMC5776724
OpenAlexW2771174445

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.